What is the significance of KRAS mutations in colon cancer?

Updated: Apr 15, 2020
  • Author: Tomislav Dragovich, MD, PhD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print

KRAS mutations, which are present in about 40% of colon adenocarcinomas, affect sensitivity to treatment with biologic agents directed against the epithelial growth factor receptor (EGFR). [68] The US Food and Drug Administration (FDA) has approved a qualitative real-time polymerase chain reaction (PCR) assay, the therascreen KRAS RGQ PCR Kit, for the detection of specific KRAS mutations in the KRAS oncogene.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!